Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM is a complex, yet relatively common, genetic heart disease that occurs in approximately 1 in 500 individuals. It affects both genders and all races. The disease results in excessive thickening of the heart muscle—referred to as “hypertrophy”—which occurs most commonly in the septum (i.e. the muscular wall that separates the left and right lower chambers of the heart). In the majority of patients, this thickening begins during puberty, with little to no change in the thickness beyond early adulthood. However, symptoms from HCM can develop or worsen at any age, but most commonly occur during mid-life.
Doctors + Care Team
Accepting New Patients
Title(s): Associate Surgical Director of the Hypertrophic Cardiomyopathy Center; Cardiac Surgeon; Assistant Professor, TUSM
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5594
Fax #: 617-636-7175
Adult cardiac surgery, hypertrophic cardiomyopathy (HCM), structural heart disease, minimally invasive valve surgery, open and endovascular aortic procedures
View Full Profile for Michael Robich, MD, MSPH
Research + Clinical Trials
This will be a double-blinded, placebo-controlled study, aiming to assess the safety and tolerability of CT-G20 in subjects with obstructive hypertrophic cardiomyopathy (oHCM).
More information about research and clinical trials
This study is a double-blinded phase 2 clinical trial for a medication dedicated to treating patients with non-obstructive hypertrophic cardiomyopathy.
More information about research and clinical trials